Scarinci Hollenbeck, LLC, LLCScarinci Hollenbeck, LLC, LLC

Client Alert

USPTO Offering Relief to IP Owners Impacted by COVID-19

Author: Scarinci Hollenbeck, LLC

Date: April 6, 2020

Key Contacts

Back

The U.S. Patent and Trademark Office (USPTO) is offering relief to intellectual property owners affected by the COVID-19 pandemic…

The U.S. Patent and Trademark Office (USPTO) is offering relief to intellectual property owners affected by the Coronavirus (COVID-19) pandemic. Most recently, the Director of the USPTO exercised his authority under the Coronavirus Aid, Relief and Economic Security (CARES) Act to extend certain statutory deadlines.

USPTO Offering Relief to IP Owners Impacted by COVID-19

“Inventors and entrepreneurs are the lifeblood of our economy, and we recognize that many of them are having difficulty as a result of the effects of COVID-19,” USPTO Director Andrei Iancu said in a press statement. “As a result, we are working to provide as much relief as possible to our stakeholders, consistent with our ability to maintain the USPTO’s fee-funded operations. We are especially mindful of the outsized impact on small businesses and independent inventors, and have provided additional relief for these groups. Ultimately, our goal is to ensure not only that inventors and entrepreneurs can weather the storm, but that they can hit the ground running once it passes.”

USPTO COVID-19 Fee Waivers

On March 16, 2020, the USPTO published a Notice stating that it considers the effects of the Coronavirus outbreak to be an “extraordinary situation” within the meaning of 37 CFR 1.183 and 37 CFR 2.146 for affected patent and trademark applicants, patentees reexamination parties, and trademark owners. This declaration allows the USPTO to provide fee waivers in certain situations where IP owners can’t meet filing deadlines to maintain their rights.

For patent applicants or patent owners who are unable to timely reply to an Office communication due to the effects of the coronavirus outbreak, resulting in the application being held abandoned or the reexamination prosecution terminated or limited, the USPTO will waive the petition fee in 37 CPR l .17(m) when the patent applicant or patent owner files the reply with a petition under 37 CPR 1.137(a). In addition to providing a copy of the Notice, the petition must include a statement that the delay in filing the reply was because the practitioner, applicant, or at least one inventor, was personally affected by the Coronavirus outbreak such that they were unable to file a timely reply.

In order to be entitled to a fee waiver, a petition to revive under 37 CFR 1.137(a) must be filed either (1) within two months after receiving a notice of abandonment or notification that reexamination has been terminated or limited or (2) within six months after the application became abandoned or the reexamination prosecution was terminated or limited, provided that no notice or notification was received. 

For trademark applications and registrations that were abandoned or canceled/expired due to the inability to timely respond to a trademark-related Office communication as a result of the effects of the Coronavirus outbreak, the USPTO will waive the petition fee to revive the abandoned application or reinstate the canceled/expired registration. For abandoned applications, the Trademark Electronic Application System (TEAS) “Petition to Revive Abandoned Application” form should be used. For canceled/expired registrations, the TEAS “Petition to the Director” form should be used. In all cases, the petition must include a statement explaining how the failure to respond to the Office communication was due to the effects of the Coronavirus outbreak.

USPTO Filing Extensions Under CARES Act

The CARES Act authorized the USPTO to extend the statutory filing deadlines in the event that the CIVID-19 pandemic “materially affects the functioning of the Patent and Trademark Office,” “prejudices the rights of applicants, registrants, patent owners or others appearing before the office” or “prevents users from filing a document or paying a fee timely.” On March 31, the USPTO exercised that authority by providing a 30-day extension of certain due dates in patent and trademarks matters having an original due date between March 27 and April 30, 2020, provided that the filing is accompanied with a statement that the delay is caused by the coronavirus outbreak. The USPTO’s patent notice is available here, and the trademark notice is available here.

According to the USPTO, a delay in filing or payment is “due to the COVID-19 outbreak” if any person associated with the matter, i.e. applicant, inventor, practitioner, was personally affected by the pandemic. Examples provided by the USPTO include office closures, cash flow interruptions, inaccessibility of files/materials, travel delays, and personal or family illness. To obtain an extension, any filing must include a statement that the delay in filing or payment was due to the COVID-19 outbreak, as defined above.

Patent Matters

  • The following patent application and reexamination proceedings are eligible for a 30-day extension: 
  • Reply to any USPTO notice issued during pre-examination processing by a small or micro-entity
  • Reply to an office action or a USPTO notice issued during examination or patent publication processing
  • Payments of issue fee
  • Filing of a notice of appeal
  • Filing of an appeal brief
  • Filing of a reply brief
  • Payment of appeal forwarding fee
  • Filing a request for an oral hearing before the Patent Trial and Appeal Board (PTAB)
  • Filing a response to a substitute examiner’s action in response to a remand from the PTAB
  • Filing an amendment to reopen prosecution in response to, or a request for rehearing of, a PTAB decision designated as including a new ground of rejection
  • Payment of maintenance fee by a small or micro-entity
  • Filing a request for rehearing of a PTAB decision

Trademark Matters

The USPTO is also extending certain deadlines related to trademark applications, registrations, and Trademark Trial and Appeals Board (TTAB) proceedings. A 30-day extension is available for filing:

We will continue to keep you abreast of all further actions which the USPTO may take in accommodation to the COVID-19 crises.

If you have questions, please contact us

If you have any questions or if you would like to discuss the matter further, please contact the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Scarinci Hollenbeck, LLC, LLC

Related Posts

See all
A Look Back at Key 2025 Changes to Delaware Corporation Law post image

A Look Back at Key 2025 Changes to Delaware Corporation Law

Senate Bill 21 This bill was enacted largely in response to high-profile litigation, such as In re Match Group (In re Match Grp., Inc. Deriv. Litig., 315 A.3d 446 (Del. 2024)) and TripAdvisor (Maffei v. Palkon, 2025 WL 384054 (Del. Feb. 4, 2025)) and to stem the recent tide of Delaware companies reincorporating in Neveda […]

Author: Scott H. Novak

Link to post with title - "A Look Back at Key 2025 Changes to Delaware Corporation Law"
New York Corporate Transparency Act: What You Need to Know for 2026 post image

New York Corporate Transparency Act: What You Need to Know for 2026

The New York Corporate Transparency Act (NYCTA) WILL NOT apply to US-registered LLCs. In recent years, there has been significant interest in identifying the “beneficial owners” of U.S. businesses to combat perceived financial crimes such as money laundering, terrorism financing, and tax fraud by ending the use of anonymous shell companies. This led to the […]

Author: Scott H. Novak

Link to post with title - "New York Corporate Transparency Act: What You Need to Know for 2026"
Executive Order Accelerates Federal Cannabis Rescheduling and Expands Medical Marijuana and Cannabinoid Research post image

Executive Order Accelerates Federal Cannabis Rescheduling and Expands Medical Marijuana and Cannabinoid Research

On December 18, 2025, President Donald Trump signed an Executive Order titled Increasing Medical Marijuana and Cannabidiol Research, marking the most consequential federal cannabis policy action in decades. While the Order does not legalize marijuana or immediately alter its status under federal law, it directs the administration to complete the long-anticipated rescheduling of cannabis under […]

Author: Daniel T. McKillop

Link to post with title - "Executive Order Accelerates Federal Cannabis Rescheduling and Expands Medical Marijuana and Cannabinoid Research"
Strict Compliance Is Necessary: NJ Public Bidding Dispute Offers Lessons for Public Entities and Contractors post image

Strict Compliance Is Necessary: NJ Public Bidding Dispute Offers Lessons for Public Entities and Contractors

In ML, Inc. v. Edison Township Board of Education, the New Jersey Appellate Division reinforced the discretion of public entities to draft and enforce timing requirements as to the dates of key bid forms that are required to be submitted with public bids.  The court upheld the Edison Township Board of Education’s decision to award a […]

Author: David L. Blank

Link to post with title - "Strict Compliance Is Necessary: NJ Public Bidding Dispute Offers Lessons for Public Entities and Contractors"
NJDEP Reproposes All Appropriate Inquiry (AAI) Due Diligence Discharge Reporting Rule: Key Implications post image

NJDEP Reproposes All Appropriate Inquiry (AAI) Due Diligence Discharge Reporting Rule: Key Implications

On November 17, 2025, the New Jersey Department of Environmental Protection (NJDEP) changed its previously proposed  rule which  would have required persons conducting All Appropriate Inquiry (AAI)(due diligence) at real properties to report any discharge of contamination discovered during the due diligence  to NJDEP and the record owner of the property.  NJDEP has now changed […]

Author: Daniel T. McKillop

Link to post with title - "NJDEP Reproposes All Appropriate Inquiry (AAI) Due Diligence Discharge Reporting Rule: Key Implications"
Federal Cannabis Rescheduling: Status, Impacts, and Strategies post image

Federal Cannabis Rescheduling: Status, Impacts, and Strategies

Recent reports indicate that President Trump is preparing to issue an executive order as early as Monday, December 15 directing his administration to finalize the long-anticipated reclassification of cannabis under the federal Controlled Substances Act (CSA) from Schedule I to Schedule III. This development follows years of regulatory review and political debate spanning multiple administrations […]

Author: Daniel T. McKillop

Link to post with title - "Federal Cannabis Rescheduling: Status, Impacts, and Strategies"

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Sign up to get the latest from our attorneys!

Explore What Matters Most to You.

Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.

Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.

Let`s get in touch!

* The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form. By providing a telephone number and submitting this form you are consenting to be contacted by SMS text message. Message & data rates may apply. Message frequency may vary. You can reply STOP to opt-out of further messaging.

Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!